Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5857826 | Regulatory Toxicology and Pharmacology | 2012 | 9 Pages |
Pioglitazone (PIO), an antidiabetic drug and olmesartan medoxomil (OLM), an antihypertensive drug were administered orally alone and in combination to Wistar albino rats for evaluation of pharmacokinetics, pharmacodynamics and repeated dose 28-day oral toxicity of individual drugs and their combination. Pharmacokinetic study was performed by orally administering PIO and OLM at single dose of 3 and 2Â mg/kg, respectively alone and in combination analyzing the plasma samples using LC-MS/MS. Antidiabetic activity evaluation was done in type-2 diabetes mellitus induced animals at same dose level as in pharmacokinetic study daily for 30Â days. PIO and/or OLM were administered orally to animals at daily doses of 50, 100 and 150Â mg/kg for 28Â days for toxicity study. There was no significant alteration in the pharmacokinetic parameters of either drug indicating absence of any pharmacokinetic interaction when co-administered. Positive pharmacodynamic interaction between PIO and OLM was established in this study. Two drugs in combination showed no evidence of potentiation of 28-day repeated dose toxicity in animals. Again, drugs, alone and in combination, caused only minor changes in clinical-laboratory tests and histopathological change was not found in the experiment performed. In conclusion, PIO and OLM combination can primarily be stated as safe in terms of present toxicity and pharmacokinetics findings.
⺠Pharmacokinetics of pioglitazone and olmesartan as singly/combination in rat. ⺠Pharmacodynamics of pioglitazone and olmesartan as singly/combination in rat. ⺠Subchronic toxicity of pioglitazone and olmesartan as singly/combination in rat.